{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:23:33Z","timestamp":1791379413050,"version":"4.3.2"},"reference-count":7,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Bupropion hydrochloride is an inhibitor of dopamine and norepinephrine, which is commonly prescribed for major depression, smoking cessation, and bipolar depression. Here we report a highly unusual case of bupropion induced knee monoarthritis in a bipolar depression patient. With bupropion XL 150 mg for 2 weeks, her left knee began to swell; at the third week, this condition was worsening. The aggravation of the left knee effusion stopped after the discontinuation of bupropion XL. The effusion and swelling disappeared after 15 ml of synovial fluid was drawn out and the effusion has never returned. Analysis of the synovial fluid showed noninflammatory effusion. Her left knee swelling was most likely due to angioedema caused by bupropion XL.<\/jats:p>","DOI":"10.64719\/pb.4066","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"85-87","source":"Crossref","is-referenced-by-count":1,"title":["Monoarthritis Induced by Bupropion Hydrochloride"],"prefix":"10.64719","volume":"44","author":[{"given":"Weiqing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Biovail Corporation. Bupropion hydrochloride: Product labeling. 10\/2008."},{"key":"ref2","unstructured":"Stahl SM. 3rd. New York, NY: Cambridge University Press; 2009. Stahl\u2019s Essential Psychopharmacology: The prescriber\u2019s Guide; pp. 57\u201362."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Jefferson JW. Bupropion extended-release for depressive disorders. Expert Rev Neurother. 2008;8(5):715\u2013722.","DOI":"10.1586\/14737175.8.5.715"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653\u2013689.","DOI":"10.2165\/00003495-200868050-00011"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Tackett AE, Smith KM. Bupropion-induced angioedema. Am J Health Syst Pharm. 2008;65(17):1627\u20131630.","DOI":"10.2146\/ajhp070575"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hack S. Pediatric bupropion-induced serum sicknesslike reaction. J Child Adolesc Psychopharmacol. 2004;14(3):478\u2013480.","DOI":"10.1089\/cap.2004.14.478"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ornetti P et al. Joint symptoms in patients on bupropion therapy. Joint Bone Spine. 2004;71(6):583\u2013585.","DOI":"10.1016\/j.jbspin.2003.10.004"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:24:36Z","timestamp":1791314676000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/monoarthritis-induced-by-bupropion-hydrochloride\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4066","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}